drugset / Trial / NCT05863585
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
Phase 1
Unknown
14 enrolled
International AIDS Vaccine Initiative
Access to Advanced Health Institute (AAHI) · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
NaSingle-groupOpen-labelPrevention
Summary
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, given to a Population of Adults in Good General Health Who have Received 3 doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Timeline
- Start
- 2023-06
- Primary completion
- 2024-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG505 SOSIP.664 gp140 | Vaccine | 100 ug | — |